AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19961726
Drug: Admission blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission blood glucose > 13.0 mmol/L
Trial: 19961726
Drug: Admission blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission blood glucose < 6.1 mmol/L in known diabetes
Trial: 19961726
Drug: Admission blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission blood glucose 6.1 to 7.7 mmol/L in known diabetes
Trial: 19961726
Drug: Admission blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission blood glucose > 13.0 mmol/L in known diabetes
Trial: 15014355
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) 500/600 mg/m + folinic acid with or without trimetrexate
Trial: 11123736
Drug: Intermittent IT
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent IT morphine (5 microg x kg(‐1) four times a day)
Trial: 11123736
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of bupivacaine (40 microg x kg(‐1) x h(‐1)) and morphine (0.6 microg x kg(‐1) x h(‐1))
Trial: 9298054
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide hydrochloride
Trial: 30328767
Drug: Neuropsychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropsychological treatment (control condition)
Trial: 26703917
Drug: Zofenopril +
RxNorm normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril + Hydrochlorothiazide (Z + H) 30 + 12.5 mg
Trial: 26703917
Drug: Irbesartan +
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan + Hydrochlorothiazide (I + H) 150 + 12.5 mg
Trial: 23117779
Drug: Prasugrel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (10 or 5 mg/d)
Trial: 23117779
Drug: Prasugrel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (5 mg/d for specific populations)
Trial: 23117779
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/d for specific populations)
Trial: 23117779
Drug: Prasugrel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (5 mg/d for older participants)
Trial: 23117779
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/d for older participants)
Trial: 20122047
Drug: Interpersonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal therapy (IPT) for minor depression
Trial: 16224053
Drug: Atorvastatin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 80 mg qd for 6 months
Trial: 16224053
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg qd for 6 months
Trial: 16337518
Drug: Pyridostigmine bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine bromide (45 mg)
Trial: 1330318
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg sumatriptan
Trial: 1330318
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg sumatriptan
Trial: 1330318
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg sumatriptan (open-label for partial or non-responders)
Trial: 3554658
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (250 mg/m2) given twice daily
Trial: 3554658
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg)
Trial: 2853038
Drug: Melatonin 100
RxNorm normalized name: melatonin 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 100 mg
Trial: 23553447
Drug: Web-based questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based questionnaire for reporting adverse drug events (ADEs)
Trial: 21701406
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (10-day regimen: omeprazole with amoxicillin for 5 days, followed by omeprazole, clarithromycin, and metronidazole for 5 days)
Trial: 21701406
Drug: Tailored triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored triple therapy (7-day regimen: omeprazole with amoxicillin and clarithromycin for CLA-susceptible strains or metronidazole for CLA-resistant strains)
Trial: 21701406
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment in CLA- and MET-susceptible strains
Trial: 21701406
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment in CLA-resistant strains
Trial: 12690904
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (2 g orally)
Trial: 11164440
Drug: C. pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pneumoniae IgG antibodies
Trial: 11164440
Drug: C. pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pneumoniae IgA antibodies
Trial: 11164440
Drug: C. pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pneumoniae antibody titres
Trial: 1589246
Drug: Nalbuphine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (0.2 mg/kg)
Trial: 1589246
Drug: Aspirin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (10 mg/kg)
Trial: 3707649
Drug: Dopamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine at increasing doses of 2, 4, and 6 micrograms/kg/min
Trial: 3707649
Drug: Ibopamine 50
RxNorm normalized name: ibopamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 50 mg (on day 1), 100 mg (on day 2), and dopamine (on day 3)
Trial: 24447651
Drug: 16 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/kg sugammadex
Trial: 24447651
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro (200 μg/mL sugammadex)
Trial: 20078487
Drug: Tiapride (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (800 mg/day)
Trial: 20078487
Drug: Lorazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (10 mg/day)
Trial: 10613304
Drug: CTRx (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTRx (5 Gy equivalent per fraction, 3-5 weekly fractions) with iodinated x-ray contrast media for dose enhancement
Trial: 7485697
Drug: 2.5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 micrograms of recombinant HB vaccine given at birth, two, and six months of age (group A)
Trial: 7485697
Drug: 2.5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 micrograms of recombinant HB vaccine given at two, four, and nine months of age (group B)
Trial: 7485697
Drug: Routine childhood
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine childhood vaccines (BCG, DPT, polio, and measles) given to all groups
Trial: 29315462
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of oral aprepitant
Trial: 29315462
Drug: Oral starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral starch (control group)
Trial: 26899608
Drug: DEX administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX administration (uni-DEX and bilateral-DEX groups)
Trial: 26899608
Drug: Saline administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administration (uni-saline group)
Trial: 23039397
Drug: Sequential (SEQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential (SEQ) breast expression
Trial: 17705848
Drug: Lubeck Reaction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeck Reaction Perimeter treatment, administered twice weekly for an average of 8.2 months, each session lasting 45 minutes.
Trial: 17705848
Drug: Monocular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monocular treatment conditions
Trial: 12718823
Drug: Clinical evaluation
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical evaluation and treatment for CAP
Trial: 9581666
Drug: Isradipine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (0, 5, and 10 mg)
Trial: 9581666
Drug: Ethanol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0, 0.5, and 1 g/kg)
Trial: 31705332
Drug: Introduction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Introduction of prescription drug co-payments (€0.50 to €2.50) for medical cardholders
Trial: 27225678
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (precontoured locking plates placed either superiorly or anteriorly)
Trial: 21857363
Drug: Tapering after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering after training (2 weeks)
Trial: 21857363
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of MTG and ETG after training and tapering
Trial: 2390429
Drug: Atropine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (both doses)
Trial: 7308274
Drug: F‐CBZ, DAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F‐CBZ, DAK (200 mg single dose)
Trial: 7308274
Drug: Tegretol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegretol (200 mg single dose)
Trial: 29241199
Drug: Darbepoetin therapy
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin therapy
Trial: 25401463
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) therapy (40 sessions at 1.5 ATA)
Trial: 23752553
Drug: Positive expiratory
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive expiratory pressure (PEP) therapy (10‐20 cm H2O)
Trial: 17318022
Drug: LCT genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT genotype CC (associated with lactose malabsorption)
Trial: 15203784
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray (fast delivery)
Trial: 15203784
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch (slow delivery)
Trial: 15203784
Drug: Placebo condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo condition (placebo spray and patch)
Trial: 15203784
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch condition (with placebo spray)
Trial: 15203784
Drug: Nicotine spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine spray condition (with placebo patch)
Trial: 11181775
Drug: HPV16 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 L1 VLP vaccine without adjuvant (10-50 microg doses)
Trial: 11181775
Drug: HPV16 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 L1 VLP vaccine with MF59 adjuvant (10-50 microg doses)
Trial: 11181775
Drug: HPV16 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 L1 VLP vaccine with alum adjuvant (10-50 microg doses)
Trial: 2114722
Drug: Adjuvant portal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant portal infusion of 5‐fluorouracil in combination with mitomycin C
Trial: 2114722
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (strict adherence)
Trial: 2114722
Drug: No or
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No or incomplete chemotherapy
Trial: 19912735
Drug: Gengnianan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gengnianan Tablet (control)
Trial: 14674971
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg(‐1) followed by remifentanil 1 microg kg(‐1) (group PR)
Trial: 14674971
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 microg kg(‐1) followed by propofol 2.5 mg kg(‐1) (group RP)
Trial: 11739068
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with nortriptyline-plus-perphenazine
Trial: 11739068
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with nortriptyline-plus-placebo
Trial: 9770818
Drug: Propofol without
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol without narcotic analgesics
Trial: 9770818
Drug: Propofol combined
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol combined with pyritramide (0.4 mg/kg)
Trial: 9770818
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of propofol
Trial: 9770818
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of thiopental
Trial: 9357148
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose choline (500 mg TDS)
Trial: 9357148
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose choline (1000 mg TDS)
Trial: 29310326
Drug: remifentanil (infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil (infused at 2 μg/kg/h)
Trial: 29310326
Drug: dexmedetomidine (infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexmedetomidine (infused at 0.4 μg/kg/h)
Trial: 16180017
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of change agents as part of the intervention.
Trial: 11413351
Drug: Formoterol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (24 microg twice daily by Turbuhaler)
Trial: 11413351
Drug: Salmeterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (100 microg twice daily by Diskhaler)
Trial: 28455162
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (sphincterotomy)
Trial: 26178282
Drug: Intraarticular etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraarticular etanercept injection
Trial: 22952137
Drug: No solution
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No solution (CON)
Trial: 21733322
Drug: PF-rich extract
RxNorm normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-rich extract (500 mg daily)
Trial: 19502035
Drug: Pre-warmed colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-warmed colloid followed by pre-warmed crystalloid solution
Trial: 19502035
Drug: Non-warmed infusion
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-warmed infusion
Trial: 16430793
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection (droperidol 2.5 mg)
Trial: 16430793
Drug: Continuous group
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous group (droperidol 2.5 mg 2 day(‐1))
Trial: 10883558
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) with breathing retraining (BR)
Trial: 10883558
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) without breathing retraining (BR)
Trial: 9166393
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate (400 mg/day for 2 weeks, followed by 11 weeks of 500 mg/day elemental oral calcium)
Trial: 9166393
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist alone (triptorelin 3.75 mg intramuscularly every 4 weeks)
Trial: 9166393
Drug: Elemental calcium
RxNorm normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental calcium (500 mg/day continuously)
Trial: 8222488
Drug: Drug-free vehicles
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free vehicles
Trial: 2988108
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (Guarem), 5 g
Trial: 2988108
Drug: Fiber-enriched wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber-enriched wheat bran (Fiberform), 10.5 g
Trial: 24832191
Drug: BAl (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAl (4.8 g day(‐1) for 4 weeks, increased to 6.4 g day(‐1) for 2 weeks)
Trial: 22877888
Drug: CBT-based stress-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-based stress-management treatment (SM)
Trial: 6886969
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg caffeine as aqueous oral solution
Trial: 6886969
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg caffeine as intravenous infusion over 30 min
Trial: 30658460
Drug: Wheat albumin
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat albumin (WA) 1.5 g
Trial: 26345338
Drug: Naltrexone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone therapy (4 weeks, oral administration)
Trial: 26345338
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 weeks, oral administration)
Trial: 23974801
Drug: ART +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART + Carisolv® gel
Trial: 22695473
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg/d) plus Twelve Step Facilitation (TSF)
Trial: 22695473
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg/d) plus standard counseling
Trial: 17580147
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg by intravenous infusion 2 hours before operation)
Trial: 11886767
Drug: Vitamin K(2)
RxNorm normalized name: vitamin K 2
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K(2) and D(3) combined therapy for 24 months
Trial: 11886767
Drug: Vitamin K(2)
RxNorm normalized name: vitamin K 2
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K(2) therapy alone for 24 months
Trial: 11886767
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving dietary therapy alone
Trial: 10334534
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT), n = 39
Trial: 10334534
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormones), n = 280
Trial: 8547939
Drug: 8% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% glucose solution (CHO)
Trial: 8547939
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (PL)